Company Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.
In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions.
It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC.
The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Country | United States |
IPO Date | Apr 2, 1991 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 14,165 |
CEO | Dr. Leonard S. Schleifer M.D., Ph.D. |
Contact Details
Address: 777 Old Saw Mill River Road Tarrytown, New York United States | |
Website | https://www.regeneron.com |
Stock Details
Ticker Symbol | REGN |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000872589 |
CUSIP Number | 75886F107 |
ISIN Number | US75886F1075 |
Employer ID | 13-3444607 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Leonard S. Schleifer M.D., Ph.D. | Co-Founder, President, Chief Executive Officer & Co-Chairman |
Bob McCowan | Senior Vice President of IT & Chief Information Officer |
Christopher R. Fenimore CPA | Senior Vice President of Finance & Chief Financial Officer |
Daniel P. Van Plew | Executive Vice President and GM of Industrial Operations & Product Supply |
Dr. Andrew J. Murphy Ph.D. | Executive Vice President of Research |
Dr. George D. Yancopoulos M.D., Ph.D. | Co-Founder, President, Chief Scientific Officer & Co-Chairman |
Joseph J. LaRosa J.D. | Executive Vice President, General Counsel & Secretary |
Melissa Lozner | Senior Vice President & Chief Compliance Officer |
Patrice Gilooly | Senior Vice President of Quality Assurance & Operations |
Ryan Crowe | Senior Vice President of Investor Relations & Strategic Analysis |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 10, 2024 | 4 | Filing |
Dec 10, 2024 | 4 | Filing |
Dec 10, 2024 | 4 | Filing |
Dec 10, 2024 | 4 | Filing |
Dec 10, 2024 | 4 | Filing |
Dec 10, 2024 | 4 | Filing |
Dec 10, 2024 | 4 | Filing |
Nov 12, 2024 | 4 | Filing |
Nov 05, 2024 | 4 | Filing |
Oct 31, 2024 | S-3ASR | Automatic shelf registration statement of securiti... |